Quarterly Sales and EPS Roundup:

Gilead Sciences, Inc. (NASDAQ:GILD) reported sales (ttm) of 31.58 Billion, whereas, 20 number of analysts estimated the mean sale of 7130.05 million. The analysts estimated sales for the higher end at 7536.5 million and lower end at 6659 million while the year ago reported sale was 8035.31 million.

8 number of analysts have estimated the sales of the company for the quarter ending Jan 31, 2017- Feb 6, 2017, analysts estimated mean sale target of 7112.58 million while high and low sale targets are estimated at 7634.2 million and 6444 million respectively.

Gilead Sciences, Inc. (NASDAQ:GILD) reported earning per shares for the quarter ending Nov 01 AMC at 2.75, whereas, 23 number of analysts estimated the mean EPS at 2.62. The analysts estimated EPS for the higher end at 2.94 and lower end at 2.36 while the year ago reported earnings per share was 3.11.

The company has mean EPS estimate of 2.63 reported by 9 number of analyst for the quarter ending Jan 31, 2017- Feb 6, 2017. The analysts estimated mean EPS at 2.63 while the high and low EPS estimate stand at 2.8 and 2.55 respectively. In contrast to the year ago quarter EPS was at 3.41. EPS long term mean growth rate estimated by 7 analysts is at -0.64%, whereas, the high and low Long term growth rate estimated at 7 and -9.2.

Valuation Ratios of Gilead Sciences, Inc. (NASDAQ:GILD) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the Gilead Sciences, Inc. (NASDAQ:GILD). These ratios are important while doing valuation of the company or the shares of the company.

Gilead Sciences, Inc. (NASDAQ:GILD) currently has P/E (Price to Earnings) ratio of 6.96 while the company’s industry has 42.21 P/E and the sector P/E is 29.87. Similarly, the company’s last 5 years high P/E ratio is 41.39 and low P/E is 8.5, whereas, the industry’s and sector’s  high P/E for the past year is 130.71 and 43.94 respectively and low P/E ratio for the last 5 years is 71.17 for the industry and 19.95 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, 62 has Beta of 1.23 while its industry and Sector’s beta remains at 0.79 and 0.83 respectively.

Price to Sale ratio of 62 stands at 3.13 while Price to Book Ratio stands at 5.88. Its Price to Cash Flow ratio shows the value of 6.09, whereas, the industry and sector ratio of Price to Cash Flow ticked at 27.02 and 22.64 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Gilead Sciences, Inc. (NASDAQ:GILD) stands at 32.64 while the industry’s and the sector’s growth for next 5 years ticked at 20.54 and 10.88 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 48.28 and 64.57.

Gilead Sciences, Inc. (NASDAQ:GILD) Trading Statistics:

The company declined -1.56% and closed its last trading session at $74.87. The market capitalization of the company is at $97.1 Billion. The stock touched 52-week High of $104.79 on Dec 17, 2015 and 52-week Low of $71.39 on Nov 4, 2016. The stock currently has Weekly Volatility of 1.65% and Monthly Volatility of 2.13%. The Beta for the company stands at 1.23 and its Average True Range (ATR) shows a value of 1.53.